rituximab,epcoritamab,lenalidomide
abbvie,genmab
['epcore,(-epcore nhl)', 'epcoritamab', 'epcore,fl,1', 'ritux', 'lymsm']
epcoritamab + len/ritux (r2) for r/r fl. fixed-duration epcori for 2 yrs. orr 95% (cr 80%!) with great pfs (although only ~6 mos of f/u thus far). great option for high-risk fl, and outpatient dosing will be done for the phase 3. (no discontinuation for aes noted). #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????